Intrinsic Disorder in Proteins with Pathogenic Repeat Expansions
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Datasheet Blank Template
SAN TA C RUZ BI OTEC HNOL OG Y, INC . DIP2A (L-16): sc-67555 BACKGROUND APPLICATIONS DIP2A (Disco-interacting protein 2 homolog A), also known as DIP2, is a 1,571 DIP2A (L-16) is recommended for detection of DIP2A of human origin by amino acid nuclear protein. It is one of three human homologs (DIP2A, DIP2B Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), and DIP2C) of the Drosophila dip2 (disconnected-interacting protein 2) protein. immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell In Drosophila , dip2 interacts with disco, a protein required for neuronal con - lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50- nections in the visual systems of larvae and adults. The closest vertebrate 1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30- homologs to disco are the basonuclin genes. In mice, DIP2 homologs show 1:3000). restricted expression to the brain. This suggests that, similar to the function DIP2A (L-16) is also recommended for detection of DIP2A, also designated of Drosphila dip2, vertebrate DIP2 homologs may play a role in the develop - Disco-interacting protein 2 homolog A, in additional species, including ment of the nervous system. Expressed ubiquitously with highest expression canine. in the brain, DIP2A is thought to function in signaling throughout the central nervous system by providing positional clues for axon patterning and pathfind - Suitable for use as control antibody for DIP2A siRNA (h): sc-62212, DIP2A ing . Four isoforms of DIP2A exist due to alternative splicing events. -
Cystatins in Immune System
Journal of Cancer 2013, Vol. 4 45 Ivyspring International Publisher Journal of Cancer 2013; 4(1): 45-56. doi: 10.7150/jca.5044 Review Cystatins in Immune System Špela Magister1 and Janko Kos1,2 1. Jožef Stefan Institute, Department of Biotechnology, Ljubljana, Slovenia; 2. University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia. Corresponding author: Janko Kos, Ph. D., Department of Biotechnology, Jožef Stefan Institute, &Faculty of Pharmacy, University of Ljubljana, Slovenia; [email protected]; Phone+386 1 4769 604, Fax +3861 4258 031. © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. Received: 2012.10.22; Accepted: 2012.12.01; Published: 2012.12.20 Abstract Cystatins comprise a large superfamily of related proteins with diverse biological activities. They were initially characterised as inhibitors of lysosomal cysteine proteases, however, in recent years some alternative functions for cystatins have been proposed. Cystatins pos- sessing inhibitory function are members of three families, family I (stefins), family II (cystatins) and family III (kininogens). Stefin A is often linked to neoplastic changes in epithelium while another family I cystatin, stefin B is supposed to have a specific role in neuredegenerative diseases. Cystatin C, a typical type II cystatin, is expressed in a variety of human tissues and cells. On the other hand, expression of other type II cystatins is more specific. Cystatin F is an endo/lysosome targeted protease inhibitor, selectively expressed in immune cells, suggesting its role in processes related to immune response. -
Anti-Cystatin B / Stefin B Antibody (ARG56897)
Product datasheet [email protected] ARG56897 Package: 100 μl anti-Cystatin B / Stefin B antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes Cystatin B / Stefin B Tested Reactivity Hu Tested Application ICC/IF, IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name Cystatin B / Stefin B Antigen Species Human Immunogen Recombinant fusion protein corresponding to aa. 1-98 of Human Cystatin B / Stefin B (NP_000091.1). Conjugation Un-conjugated Alternate Names Liver thiol proteinase inhibitor; EPM1; CPI-B; EPM1A; Cystatin-B; Stefin-B; PME; CST6; ULD; STFB Application Instructions Application table Application Dilution ICC/IF 1:50 - 1:200 IHC-P 1:50 - 1:200 WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control MCF7 and DU145 Calculated Mw 11 kDa Observed Size 14 kDa Properties Form Liquid Purification Affinity purified. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/3 Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol CSTB Gene Full Name cystatin B (stefin B) Background The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences. -
Regulation of Cdc42 and Its Effectors in Epithelial Morphogenesis Franck Pichaud1,2,*, Rhian F
© 2019. Published by The Company of Biologists Ltd | Journal of Cell Science (2019) 132, jcs217869. doi:10.1242/jcs.217869 REVIEW SUBJECT COLLECTION: ADHESION Regulation of Cdc42 and its effectors in epithelial morphogenesis Franck Pichaud1,2,*, Rhian F. Walther1 and Francisca Nunes de Almeida1 ABSTRACT An overview of Cdc42 Cdc42 – a member of the small Rho GTPase family – regulates cell Cdc42 was discovered in yeast and belongs to a large family of small – polarity across organisms from yeast to humans. It is an essential (20 30 kDa) GTP-binding proteins (Adams et al., 1990; Johnson regulator of polarized morphogenesis in epithelial cells, through and Pringle, 1990). It is part of the Ras-homologous Rho subfamily coordination of apical membrane morphogenesis, lumen formation and of GTPases, of which there are 20 members in humans, including junction maturation. In parallel, work in yeast and Caenorhabditis elegans the RhoA and Rac GTPases, (Hall, 2012). Rho, Rac and Cdc42 has provided important clues as to how this molecular switch can homologues are found in all eukaryotes, except for plants, which do generate and regulate polarity through localized activation or inhibition, not have a clear homologue for Cdc42. Together, the function of and cytoskeleton regulation. Recent studies have revealed how Rho GTPases influences most, if not all, cellular processes. important and complex these regulations can be during epithelial In the early 1990s, seminal work from Alan Hall and his morphogenesis. This complexity is mirrored by the fact that Cdc42 can collaborators identified Rho, Rac and Cdc42 as main regulators of exert its function through many effector proteins. -
1 Running Head
medRxiv preprint doi: https://doi.org/10.1101/2020.09.16.20194639; this version posted August 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . RUNNING HEAD: Alcohol use disorder dual methylation study Dual methylation and hydroxymethylation study of alcohol use disorder Shaunna L. Clark1, Robin F. Chan2, Min Zhao2, Lin Y. Xie2, William E. Copeland3, Brenda W.J.H. Penninx3, Karolina A. Aberg2, Edwin J.C.G. van den Oord2 1Department of Psychiatry, Texas A&M University 2Center for Biomarker Research and Precision Medicine, Virginia Commonwealth University 3 Department of Psychiatry, University of Vermont 4 Department of Psychiatry, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands Corresponding Author: Shaunna L. Clark, Email: [email protected]; Address: 8441 Riverside Parkway, Bryan, TX, 77807; Phone: (979) 436-0179 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2020.09.16.20194639; this version posted August 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . ABSTRACT Using an integrative, multi-tissue design we sought to characterize methylation and hydroxymethylation changes in blood and brain associated with alcohol use disorder (AUD). -
Design of a Bioactive Small Molecule That Targets R(AUUCU) Repeats in Spinocerebellar Ataxia 10
ARTICLE Received 24 Jun 2015 | Accepted 18 Apr 2016 | Published 1 Jun 2016 DOI: 10.1038/ncomms11647 OPEN Design of a bioactive small molecule that targets r(AUUCU) repeats in spinocerebellar ataxia 10 Wang-Yong Yang1, Rui Gao2, Mark Southern3, Partha S. Sarkar2 & Matthew D. Disney1 RNA is an important target for chemical probes of function and lead therapeutics; however, it is difficult to target with small molecules. One approach to tackle this problem is to identify compounds that target RNA structures and utilize them to multivalently target RNA. Here we show that small molecules can be identified to selectively bind RNA base pairs by probing a library of RNA-focused small molecules. A small molecule that selectively binds AU base pairs informed design of a dimeric compound (2AU-2) that targets the pathogenic RNA, expanded r(AUUCU) repeats, that causes spinocerebellar ataxia type 10 (SCA10) in patient- derived cells. Indeed, 2AU-2 (50 nM) ameliorates various aspects of SCA10 pathology including improvement of mitochondrial dysfunction, reduced activation of caspase 3, and reduction of nuclear foci. These studies provide a first-in-class chemical probe to study SCA10 RNA toxicity and potentially define broadly applicable compounds targeting RNA AU base pairs in cells. 1 Departments of Chemistry and Neuroscience, The Scripps Research Institute, Scripps Florida, Jupiter, Florida 33458, USA. 2 Mitchell Center for Neurodegenerative Disorders, Department of Neurology, Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, Texas 77555, USA. 3 Informatics Core, The Scripps Research Institute, Scripps Florida, Jupiter, Florida 33458, USA. Correspondence and requests for materials should be addressed to M.D.D. -
Bhagwan Moorjani, MD, FAAP, FAAN • Requires Knowledge of Normal CNS Developmental (I.E
1/16/2012 Neuroimaging in Childhood • Neuroimaging issues are distinct from Pediatric Neuroimaging in adults Neurometabolic-degenerative disorder • Sedation/anesthesia and Epilepsy • Motion artifacts Bhagwan Moorjani, MD, FAAP, FAAN • Requires knowledge of normal CNS developmental (i.e. myelin maturation) • Contrast media • Parental anxiety Diagnostic Approach Neuroimaging in Epilepsy • Age of onset • Peak incidence in childhood • Static vs Progressive • Occurs as a co-morbid condition in many – Look for treatable causes pediatric disorders (birth injury, – Do not overlook abuse, Manchausen if all is negative dysmorphism, chromosomal anomalies, • Phenotype presence (syndromic, HC, NCS, developmental delays/regression) systemic involvement) • Predominant symptom (epilepsy, DD, • Many neurologic disorders in children weakness/motor, psychomotor regression, have the same chief complaint cognitive/dementia) 1 1/16/2012 Congenital Malformation • Characterized by their anatomic features • Broad categories: based on embryogenesis – Stage 1: Dorsal Induction: Formation and closure of the neural tube. (Weeks 3-4) – Stage 2: Ventral Induction: Formation of the brain segments and face. (Weeks 5-10) – Stage 3: Migration and Histogenesis: (Months 2-5) – Stage 4: Myelination: (5-15 months; matures by 3 years) Dandy Walker Malformation Dandy walker • Criteria: – high position of tentorium – dysgenesis/agenesis of vermis – cystic dilatation of fourth ventricle • commonly associated features: – hypoplasia of cerebellum – scalloping of inner table of occipital bone • associated abnormalities: – hydrocephalus 75% – dysgenesis of corpus callosum 25% – heterotropia 10% 2 1/16/2012 Etiology of Epilepsy: Developmental and Genetic Classification of Gray Matter Heterotropia Cortical Dysplasia 1. Secondary to abnormal neuronal and • displaced masses of nerve cells • Subependymal glial proliferation/apoptosis (gray matter) heterotropia (most • most common: small nest common) 2. -
(12) Patent Application Publication (10) Pub. No.: US 2007/0254315 A1 Cox Et Al
US 20070254315A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0254315 A1 Cox et al. (43) Pub. Date: Nov. 1, 2007 (54) SCREENING FOR NEUROTOXIC AMINO (60) Provisional application No. 60/494.686, filed on Aug. ACID ASSOCATED WITH NEUROLOGICAL 12, 2003. DSORDERS Publication Classification (75) Inventors: Paul A. Cox, Provo, UT (US); Sandra A. Banack, Fullerton, CA (US); Susan (51) Int. Cl. J. Murch, Cambridge (CA) GOIN 33/566 (2006.01) GOIN 33/567 (2006.01) Correspondence Address: (52) U.S. Cl. ............................................................ 435/721 PILLSBURY WINTHROP SHAW PITTMAN LLP (57) ABSTRACT ATTENTION: DOCKETING DEPARTMENT Methods for screening for neurological disorders are dis P.O BOX 105OO closed. Specifically, methods are disclosed for screening for McLean, VA 22102 (US) neurological disorders in a Subject by analyzing a tissue sample obtained from the subject for the presence of (73) Assignee: THE INSTITUTE FOR ETHNO elevated levels of neurotoxic amino acids or neurotoxic MEDICINE, Provo, UT derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neu (21) Appl. No.: 11/760,668 rological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a Subject, by deter (22) Filed: Jun. 8, 2007 mining the levels of B-N-methylamino-L-alanine (BMAA) Related U.S. Application Data in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neuro (63) Continuation of application No. 10/731,411, filed on logical disorders are disclosed. Methods for inhibiting, treat Dec. 8, 2003, now Pat. No. 7,256,002. -
A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated. -
KAT6A Amplifications Are Associated with Shorter Progression-Free Survival and Overall Survival in Patients with Endometrial Serous Carcinoma
PLOS ONE RESEARCH ARTICLE KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma 1 2 2 2 2 Ozlen Saglam , Zhenya Tang , Guilin Tang , L. Jeffrey Medeiros , Gokce A. TorunerID * 1 Department of Surgical Pathology, Moffitt Cancer Center, Tampa, Florida, United States of America, 2 Department of Hematopathology, Section of Clinical Cytogenetics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America * [email protected] a1111111111 a1111111111 Abstract a1111111111 a1111111111 Somatic copy number alterations (CNA) are common in endometrial serous carcinoma a1111111111 (ESC). We used the Tumor Cancer Genome Atlas Pan Cancer dataset (TCGA Pan Can) to explore the impact of somatic CNA and gene expression levels (mRNA) of cancer-related genes in ESC. Results were correlated with clinico-pathologic parameters such as age of onset, disease stage, progression-free survival (PFS) and overall survival (OS) (n = 108). OPEN ACCESS 1,449 genes with recurrent somatic CNA were identified, observed in 10% or more tumor Citation: Saglam O, Tang Z, Tang G, Medeiros LJ, samples. Somatic CNA and mRNA expression levels were highly correlated (r> = 0.6) for Toruner GA (2020) KAT6A amplifications are 383 genes. Among these, 45 genes were classified in the Tier 1 category of Cancer associated with shorter progression-free survival and overall survival in patients with endometrial Genome Census-Catalogue of Somatic Mutations in Cancer. Eighteen of 45 Tier 1 genes serous carcinoma. PLoS ONE 15(9): e0238477. had highly correlated somatic CNA and mRNA expression levels including ARNT, PIK3CA, https://doi.org/10.1371/journal.pone.0238477 TBLXR1, ASXL1, EIF4A2, HOOK3, IKBKB, KAT6A, TCEA1, KAT6B, ERBB2, BRD4, Editor: JesuÂs Maria Paramio, CIEMAT, SPAIN KEAP1, PRKACA, DNM2, SMARCA4, AKT2, SS18L1. -
A Private 16Q24.2Q24.3 Microduplication in a Boy with Intellectual Disability, Speech Delay and Mild Dysmorphic Features
G C A T T A C G G C A T genes Article A Private 16q24.2q24.3 Microduplication in a Boy with Intellectual Disability, Speech Delay and Mild Dysmorphic Features Orazio Palumbo * , Pietro Palumbo , Ester Di Muro, Luigia Cinque, Antonio Petracca, Massimo Carella and Marco Castori Division of Medical Genetics, Fondazione IRCCS-Casa Sollievo della Sofferenza, San Giovanni Rotondo, 71013 Foggia, Italy; [email protected] (P.P.); [email protected] (E.D.M.); [email protected] (L.C.); [email protected] (A.P.); [email protected] (M.C.); [email protected] (M.C.) * Correspondence: [email protected]; Tel.: +39-088-241-6350 Received: 5 June 2020; Accepted: 24 June 2020; Published: 26 June 2020 Abstract: No data on interstitial microduplications of the 16q24.2q24.3 chromosome region are available in the medical literature and remain extraordinarily rare in public databases. Here, we describe a boy with a de novo 16q24.2q24.3 microduplication at the Single Nucleotide Polymorphism (SNP)-array analysis spanning ~2.2 Mb and encompassing 38 genes. The patient showed mild-to-moderate intellectual disability, speech delay and mild dysmorphic features. In DECIPHER, we found six individuals carrying a “pure” overlapping microduplication. Although available data are very limited, genomic and phenotype comparison of our and previously annotated patients suggested a potential clinical relevance for 16q24.2q24.3 microduplication with a variable and not (yet) recognizable phenotype predominantly affecting cognition. Comparing the cytogenomic data of available individuals allowed us to delineate the smallest region of overlap involving 14 genes. Accordingly, we propose ANKRD11, CDH15, and CTU2 as candidate genes for explaining the related neurodevelopmental manifestations shared by these patients. -
Huntington's Disease Like-2: Review and Update
Review Article 1 Huntington’s Disease Like-2: Review and Update Russell L. Margolis1,2,3, Dobrila D. Rudnicki1, and Susan E. Holmes1 Abstract- Huntington’s Disease-like 2 (HDL2), like Huntington’s disease (HD), is an adult onset, progres- sive, neurodegenerative autosomal dominant disorder clinically characterized by abnormal movements, dementia, and psychiatric syndromes. Like HD, the neuropathology of HDL2 features prominent cortical and striatal atrophy and intranuclear inclusions. HDL2 is generally rare, accounting for only a few percent of HD-like cases in which the HD mutation has already been excluded. However, the rate is considerably higher among individuals of African ancestry, and is almost as common as HD in Black South Africans. The disorder is caused by a CTG/CAG expansion mutation on chromosome 16q24.3, with normal and expanded repeat ranges similar to HD, and a correlation between repeat length and onset age very similar to HD. Surprisingly, the available evidence suggests that HDL2 is not a polyglutamine disease. Rather, the repeat expansion is located within Junctophilin-3 in the CTG orientation. The phenotypic similarities between HD and HDL2 suggest that understanding the pathobiology of HDL2 may shed new light on the pathogenesis of HD and other disorders of striatal neurodegeneration. Key Words: Huntington’s disease Like-2, Huntington disease, Neurodegeneration, Neurogenetic disease Acta Neurol Taiwan 2005;14:1-8 INTRODUCTION sis(3,4). Neuronal loss is also present in the cerebral cor- tex, particularly in layers III, V, and VI(5) and to a milder Huntington’s disease, first described by George degree in globus pallidus, thalamus, subthalamic nucle- Huntington in 1872 is characterized by a triad of move- us, and substantia nigra.